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In some parts of Africa, 50% of deaths attributed to malaria occur in infants less than 8 mo. Thus, immunization against malaria may have to begin in the neonatal period, when neonates have maternally acquired Abs against malaria parasite proteins. Many malaria vaccines in development rely upon CD8 cells as immune effectors. Some studies indicate that neonates do not mount optimal CD8 cell responses. We report that BALB/c mice first immunized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA vaccine mixed with a plasmid expressing murine GM-CSF (DG) and boosted at 28 days with poxvirus expressing PyCSP were protected (93%) as well as mice immunized entirely as adults (70%). Protection was dependent on CD8 cells, and mice had excellent anti-PyCSP IFN-␥ and cytotoxic T lymphocyte responses. Mice born of mothers previously exposed to P. yoelii parasites or immunized with the vaccine were protected and had excellent T cell responses. These data support assessment of this immunization strategy in neonates/young infants in areas in which malaria exacts its greatest toll. The Journal of Immunology, 2003, 171: 3148 -3153. P lasmodium falciparum is the most virulent species of the four malaria parasite species that infect humans, being responsible for 500 million new infections and 1-3 million deaths annually (1) . In many parts of the world, more than half the mortality of malaria occurs in infants. Thus, to be optimally effective, a malaria vaccine will have to be effective in infants, and immunization may have to be initiated in the neonatal period.
P. falciparum DNA vaccines have been shown to be immunogenic in humans (2, 3) , and strategies in which DNA vaccines are boosted with recombinant poxvirus expressing the same proteins have been shown to be protective in mice (4 -6) and nonhuman primates (7) . Vaccines based on this strategy have now entered human clinical trials (8) .
Most infants who will be immunized in malaria-endemic areas will be born to mothers with previous malaria experience and immunity. The efficacy of malaria vaccines in neonates and infants in malaria-endemic areas could be adversely affected by maternally acquired Abs against the vaccine Ags (9 -12) and the immaturity of infants' immune systems (13) .
Mice first immunized as neonates have been useful in studying the effect of maternal Abs and immune immaturity on vaccine responses to human diseases such as tetanus, respiratory syncytial virus, and measles (10) . We therefore used the Plasmodium yoelii murine malaria model to study the efficacy of immunizing (priming) 7-day-old neonatal mice with a DNA plasmid expressing the P. yoelii circumsporozoite protein (PyCSP) 3 and boosting them at the age of 28 days with a recombinant poxvirus expressing the PyCSP. This specific regimen was chosen for study in neonatal mice, because our extensive previous studies (4, 6, 14) have demonstrated it to be much more effective than any other regimen we have assessed in eliciting the CD8 T cell responses, we and others consider it to be critical for protective immunity against the liver stages of Plasmodium sp. parasites (15, 16) . Also this has been the most protective regimen we have assessed in the P. yoelii system (4 -6, 14) . Our studies demonstrated that priming of 7-day-old pups from either nonimmune or immune mothers with the PyCSP prime-boost regimen and boosting them with recombinant poxvirus at 28 days of age resulted in excellent CD8 T cell responses and protection.
Materials and Methods

Mice
Eight-week-old BALB/cByJ mice purchased from The Jackson Laboratory (Bar Harbor, ME) were bred to produce pups. Breeding cages were checked daily and new births were recorded.
Parasites and infections
P. yoelii 17XNL nonlethal strain, clone 1.1 sporozoites were obtained by dissection of Anopheles stephensi salivary, as described (17) . For challenge of immunized mice, 50 sporozoites were injected into the tail vein 2 wk postimmunization. Giemsa-stained blood films were prepared and evaluated on days 5-14 postchallenge. Up to 50 oil-immersion fields (ϫ1000) were examined before calling a slide negative. Protection was defined as the complete absence of blood-stage parasitemia at all time points. Before mating, some adult females were infected by injecting 10,000 sporozoites. All had positive blood films on day 7, and negative blood films on day 21.
Immunogens and immunizations
The plasmid DNA constructs encoding the P. yoelii circumsporozoite protein (pPyCSP), designated as D; the murine GM-CSF plasmid, designated as G; the recombinant attenuated vaccinia virus (COPAK) construct encoding the PyCSP designated in this work as V; control empty plasmid; and control virus have been described (4, 6, 18) . The doses of D (100 g), G (30 g), and V (2 ϫ 10 7 PFUs) were always the same. In all cases, immunizations were administered at 3-wk intervals. D and DG (a mixture of D and G) were injected i.m. in two 25-l injections, one in each tibialis anterior muscle using a 0.3-ml insulin syringe and 29 -1/2-gauge needle. V was delivered i.p. in 0.1 ml PBS using a 1-ml insulin syringe with a 26 -1/2-gauge needle. Mice either received DG as the first dose and V as the second dose (DGV), or D as the first and second doses (DD).
Groups
Before mating, adult female mice (mothers) had either been infected with P. yoelii parasites and been shown to have cleared the parasites without intervention (mother:recovered); primed with DG and boosted with V 3 wk later (mother:DGV); primed with D and boosted with D 3 wk later (mother: DD); or had no intervention (mother:naive). These mothers were mated with naive males to produce pups between 3 and 9 wk after either documented recovery from infection or last immunization. The gestation period was 3 wk. Neonates in this study refer to 7-day-old pups (19) . Seven-to eleven-week-old adult naive BALB/c mice were also immunized and included in some studies.
Ab assays
P. yoelii sporozoite and erythrocytic stage-specific Abs in sera were assayed by immunofluorescent staining of air-dried P. yoelii sporozoites or infected erythrocytes (4).
ELISPOT assay for detecting IFN-␥-secreting CD8 cells
P. yoelii CTL MHC-restricted epitope-specific IFN-␥-producing CD8 cells were determined, as described (4) . Briefly, freshly isolated spleen cells from mice that had received their second immunization 14 days earlier were used. Measurements were made after 36 h of incubation of spleen cells with irradiated P815 cells pulsed with 1 M of the P. yoelii CTL synthetic peptide SYVPSAEQI. Spleen cells were also incubated with unpulsed irradiated P815 target cells to serve as controls. The number of Ag-specific spots (number of spots with peptide-pulsed targets minus the number of spots with unpulsed targets) corresponding to IFN-␥-producing cells in wells was enumerated using the Zeiss (Oberkochen, Germany) ELISPOT reader. The results were expressed as the number of IFN-␥-secreting cells per 10 6 spleen cells.
Ex vivo CTL assays
Ex vivo CTL assays (no period of in vitro incubation) were conducted, as previously described (4), using E:T ratios of 150:1, 75:1, and 38:1.
In vivo depletion of CD8 cells
Neonates were primed with DG and boosted with V 3 wk later, and depleted of CD8 cells in vivo before challenge with infective sporozoites 2 wk after boost. Mice received single daily i.p. injections of 0.5 mg of mAb 2.43 for 3 consecutive days (6) and then were challenged with sporozoites. Control mice received control rat Ig. PBMCs were prepared from three mice in each group, and microfluorometric analysis (FACS) was done to confirm the effectiveness of the in vivo depletions 3 days after the last Ab injection.
Statistical analysis
For protective efficacy, proportions of infected vs noninfected animals in control and experimental groups were compared using the 2 or Fisher exact test (two tailed) as appropriate. To compare relative immunogenicity of the vaccine in the different pups studied, mean values were compared using independent samples t test. SPSS for windows, version 8.0, was used for all statistical analysis.
Results
Kinetics of maternal Abs transferred to pups
To evaluate the effect of different levels of maternal Ab on immunization, we followed the kinetics of maternally transferred Abs in neonates. Sera were prepared from mice from two litters for weeks 1 and 2 bleeds. Weeks 3, 5, 8, and 10 bleeds came from mice in a single litter. An example of the kinetics of anti-sporozoite and a Sera were prepared from mice from two different litters for weeks 1 and 2 bleeds, because these mice were euthanized to obtain serum. Weeks 3, 5, 8, and 10 bleeds were done on mice from the same litter. Individual (pups and mother) and geometric mean (pups) IFA titers against air-dried P. yoelii sporozoites (spz) and asexual stage, parasitized erythrocytes (prbc) are shown. a Sera were prepared from mice from three different litters because mice bled for the 1-and 2-wk time points were euthanized at the time of acquisition of serum. Sera for the weeks 3, 5, and 10 bleeds came from mice from the same litter. Individual (pups and mother) and geometric mean (pups) IFA titers against air-dried P yoelii sporozoites are shown.
anti-erythrocytic stage Abs in neonates born to mothers previously infected with P. yoelii (mother:recovered) is shown in Table I . Ab titers were highest in sera from 2-wk-old mice. Table II outlines the anti-sporozoite Ab levels in pups born from mothers previously immunized by priming with a mixture of pPyCSP (D) plus GM-CSF plasmid (G) (day 0) and boosting with recombinant attenuated vaccinia virus expressing PyCSP (V) 3 wks later (mother: DGV). Titers were highest at 2 wk after birth.
Immune responses to DNA prime, recombinant pox boost regimen (DGV)
Anti-parasite Ab response. Table III shows representative data on the Ab titers to sporozoites by the indirect fluorescent Ab test in mice 2 wk after boost in the different groups of neonates studied simultaneously. Geometric mean Ab titers after immunization were significantly higher (mean difference significant at the p Ͻ 0.05 level) in the immunized pups born to naive mothers (mother: naive) (27,024), compared with the levels measured in the pups born to mother:recovered (6,089), mother:DGV (1,560), or mothers who were primed with pPyCSP (D) (day 0) and boosted with pPyCSP (D) 3 wk later (mother:DD) (7,241). The geometric mean Ab titers of pups from mother:DGV were significantly lower than those in pups from mother:recovered and mother:DD ( p Ͻ 0.05). The geometric mean Ab titers of pups from mother:recovered and mother:DD mothers did not differ significantly (Table III) . CD8 T cell responses. Protection against sporozoite challenge conferred by either plasmid DNA or DNA prime/poxvirus boost vaccination is dependent on CD8 T cells and IFN-␥ (6). The best correlates of protection have been IFN-␥ and ex vivo CTL activity specific for the CD8 T cell epitope, PyCSP (280-288) (SYVP-SAEQI) (4). We therefore characterized T cells from immunized mice in IFN-␥ ELISPOT and direct ex vivo CTL (chromium release) assays 2 wk after the viral boost. Immunized adults were tested simultaneously to compare their responses with those obtained in the four different pups primed when they were only 7 days old. The IFN-␥ activity and ex vivo CTL activity were assayed using splenocytes from five to eight individual mice per group, and results are depicted in Fig. 1, A and B. T cell responses were similar in mice first immunized as adults and those first immunized as neonates, regardless of the immune status of the mother.
Protection against sporozoite challenge by maternally transferred Abs
We next assessed whether maternally transferred Abs provided protection. To achieve this, pups born to mother:recovered were challenged with 50 infectious P. yoelii sporozoites i.v. 2 wk after they were born, at a time when they were still being nursed, and had the highest level of maternally acquired Abs. In one litter, 6 of FIGURE 1. CD8 T cell responses in DGV-immunized mice. A, IFN-␥-producing cells in ELIS-POT. Mice born of mothers never exposed to P. yoelii or immunized with a P. yoelii vaccine (mother:naive), or from mothers previously exposed (mother:recovered) or immunized (mother:DGV or mother:DD) (see Materials and Methods) were immunized on day 7 with D or DG and boosted with V on day 28. Immunized adult mice (Adults) were the positive controls, and unimmunized mice were the negative controls (Control). Spleen cells from individual mice, five to eight immunized mice per group, were obtained 2 wk after the recombinant poxvirus boost (V). The number of Ag-specific IFN-␥-producing cells was determined and expressed as the number of spot-forming cells per million spleen cells. (The error bars indicate the SD of the mean counts.) B, Ex vivo CTL assay. Spleen cells from same mice used for the ELISPOT assay were used directly as effectors in a chromium release ex vivo CTL assay (see Materials and Methods). Data are presented as net percentage of specific lysis at 150:1 E:T ratio. For both the IFN-␥ ELISPOT and ex vivo CTL assays, the mean spotforming cells per million and the mean net specific lysis for each of the six groups were compared in a one-way ANOVA (with Scheffe post hoc test). The only significant differences seen were between the control group and each of the other five immunized groups, p values ranging between 0.003 and Ͻ0.0009. a Seven days after birth, pups were primed with DG and 21 days later were boosted with V; 2 wk after the V boost, sera were prepared and used in IFAT against air-dried P. yoelii sporozoites. Titers of individual sera and geometric mean (GM) titers are shown. The four different mothers had either never been exposed to malaria or immunization (mother:naive), been exposed to infection (mother:recovered), or been immunized with DGV (mother:DGV) or two doses of the DNA vaccine (mother: DD), as described in Materials and Methods.
6 pups born to mother:recovered were completely protected against sporozoite challenge (Table IV) . However, upon rechallenge at 26 days after first challenge, i.e., 40 days after birth, all but 1 mouse became infected, although 4 of 5 had a slight prolongation of prepatent period. In the two challenges, 10 of 10 age-matched control mice, born to naive mothers, became infected with bloodstage parasites 5 days after sporozoite injection. The experiment was repeated, and in a second litter, only 1 of 7 pups born to mother:recovered was completely protected against the sporozoite challenge (Table IV) , and the remaining 6 had delayed patency. No mice from three different litters from mother:DGV were protected against challenge with sporozoites 2 or 3 wk after birth (data not shown).
Protection of neonatal mice by DNA prime, recombinant pox boost
Neonates from different litters from mother:naive and adult mice were immunized at the same time. Experiments were repeated using different litters, and representative data showing the results of a In two different experiments, 21 days after female mice had been infected by i.v. injection of 10,000 P. yoelii sporozoite at a time when their blood smears were negative, the females were paired with naive males mother No. 1 and mother No. 2 (both mother:recovered), and produced pups at 38 and 36 days, respectively, after mating with naive males. On day 13 after birth, sera were prepared from pups and on day 14, pups were challenged with 50 P. yoelii sporozoites. They were evaluated for up to 14 days to detect parasitemia. Twenty-six days (day 40 of life) after the first challenge, all protected mice were rechallenged with 50 P. yoelii sporozoites. IFA titers against air-dried P. yoelii sporozoites and infected red blood stages of individual sera and their geometric mean titers are reported. During the first challenge, 10 2-wk-old pups born to naive mothers became infected on day 5 after challenge. In the rechallenge, all 10 age-matched mice born to naive mothers became infected after challenge. Table V a In experiment A, 7-day-old pups born to naive mothers, and 7-wk-old adult mice were primed with a mixture of pPyCSP (D) and pGM-CSF (G), boosted with recombinant attenuated vaccinia virus expressing PyCSP (V) 3 wk later (DGV), and challenged 2 wk later with 50 P. yoelii sporozoites. In experiment B, 7-day-old pups born to naive mothers were immunized with DGV regimen and treated with mAbs to CD8 cells or control Abs prior to challenge with sporozoites. In experiment C, 7-day-old pups born to different immune mothers, Mother:Recovered, Mother:DGV, or Mother:DD were immunized with the DGV immunization regimen and challenged 2 wk later with 50 Py sporozites. Seven-day-old pups from different litters from mothers with similar immunological background received control immunizations which consisted of priming with control plasmids followed by boosting with control virus (no PyCSP insert). Ten naive infectivity control age-matched mice were also challenged.
protection after challenge are outlined in Table V , experiment A. Protection of neonates from mother:naive and adults by DGV immunization regimen was similar (neonates, 13 of 14 mice protected (93%), and adults, 7 of 10 mice protected (70%); comparison of neonates vs adults p ϭ 0.272, Fisher's exact test, two-tailed). CD8 depletion eliminated protection in 10 of 11 neonatal mice that received the DGV (Table V, experiment B). Immunization of mother: naive neonates with two doses of pPyCSP (DD) gave no protection (data not shown). Two doses of pPyCSP (DD) given at a 3-wk interval give little to no protection of adult BALB/c mice (6) .
To determine whether the DGV immunization regimen could induce CD8
ϩ T cell-dependent protection immune responses in neonates born of previously infected (mother:recovered) or previously immunized mothers (mother:DGV and mother:DD), pups from these mothers were immunized with DG at 7, and V at 28 days after birth, and challenged 2 wk after the V boost (i.e., 42 days after birth). Because without further immunization pups born of these mothers were not protected when challenged at 40 days after birth, we expected that any protection after immunization with DGV would be due to the vaccine, and not passively transferred maternal Abs. The proportion and percentages of mice protected in the different neonatal groups are shown in Table V , experiment C. Protection was 63% (10/16) for those born to mother:recovered; 81% (13/16) for those born to mother:DGV; and 88% (7/8) for those born to mothers:DD. Protection in all groups was attributable to the DGV immunization because all neonates with similar background that received the control plasmids and virus were not protected after challenge. In addition, 10 of 10 pups born to mothers who had received no immunizations nor infection (mother:naive) were also challenged simultaneously, and all became infected. Although immunizations started when pups were 7 days old (neonates), at the time of challenge all mice were 42 days old (adults).
Discussion
For the first 2-4 mo after birth, infants born of immune mothers in P. falciparum-endemic areas rarely develop severe or fatal malaria. A major protective factor is thought to be maternally acquired Abs that provide enough protection to limit morbidity and mortality. However, in areas with extremely intense transmission of P. falciparum, such as northern Ghana (20) and western Kenya (21), a significant proportion of serious disease and P. falciparumassociated mortality occurs between 4 and 8 mo of age. This means that to be optimally effective in preventing serious morbidity and mortality, a P. falciparum vaccine will have to be first administered to neonates or young infants, and the immunization series will have to be completed by 4 -6 mo of age. For logistic reasons, this means that the vaccine will have to be administered as part of the expanded program for immunization.
There are two major concerns regarding administration of a vaccine to individuals this young. The first is that the same maternally acquired Abs that protect against infection will interact with the vaccine proteins and render them nonimmunogenic, thereby limiting the immunogenicity and protective efficacy of the vaccine (9 -12). The second is that particularly for a vaccine designed to induce protective T cell responses, neonates and infants will not be able to mount such protective T cell responses after immunization because of immaturity of their immune systems (13) .
To begin to model the situation in the field, we conducted studies in three groups of mice: 1) neonatal mice born of mothers that were naive to Plasmodium sp. infection or vaccines; 2) neonates born of mothers that had previously been infected and recovered from a rodent malaria parasite, P. yoelii; or 3) neonates born of mothers immunized with the same P. yoelii vaccine that their offspring later received.
The studies reported in this work demonstrated that BALB/c mice first immunized at 7 days of age (neonatal) with a PyCSP DNA vaccine and boosted 3 wk later with a recombinant poxvirus expressing the PyCSP mounted protective immune responses comparable to mice first immunized with DNA vaccines at 6 wk of age (adult) and boosted 3 wk later. Furthermore, mice born of mothers previously exposed to P. yoelii or immunized with the PyCSP DNA prime-poxvirus boost approach were protected by the primeboost immunization regimen as well as mice born of malaria and vaccination naive mothers.
Protection of adult mice after immunization with the PyCSP DNA prime-poxvirus boost vaccine is dependent on CD8 cells and IFN-␥ (6). As compared with adult mice, the mice first immunized as neonates had similar levels of protective immunity (Tables V, experiment A), IFN activity (Fig. 1a) , and ex vivo CTL activity (Fig. 1b) . Furthermore, protection against sporozoite challenge was dependent on CD8 T cells (Table V, experiment B) .
Interestingly, Ab responses in the mice born of immune mothers were significantly lower than Ab responses in mice born of naive mothers (Table III) . Furthermore, Ab responses in mice born of naive mothers and first immunized at 7 days of age were significantly lower than Ab responses found in adult mice. In the experiment depicted in Table V , experiment A, the geometric mean titer in immunized neonates, 24,963 was at least 4 times lower than it was in immunized adults, 108,044 ( p ϭ 0.013). These data suggest that maternally acquired Abs led to Ag neutralization and reduction of Ab responses, but not T cell responses. They also suggest that the capacity of mice first immunized as neonates to produce Ab responses, but not T cell responses, is reduced as compared with adult mice. We have no data to explain why the mice born of immune mothers made good T cell responses, but not Ab responses, as compared with the mice born of naive mothers. One explanation is that the Ab responses require intact Ag, whereas the T cell responses, which are elicited by processed peptides bound to MHC molecules, were unaffected by Ag/Ab interactions.
In malaria-endemic areas, it is widely believed that infants acquire immunity passively from their mothers and are protected from malaria during the early months of life. We showed that maternally acquired Ab apparently protected pups challenged at 2 wk after birth, but the protection was short-lived. There was no detectable protection at 40 days after birth. In the Plasmodium berghei white rat model system, mothers transferred immunity to their newborns (22) . In an area of intense and perennial malaria transmission, infections in older infants lasted longer than those contracted during the first 2 mo of life (23) . Other studies have reported no correlation between the age of onset of malaria and the level of cord serum total IgG, IgM, and Abs to P. falciparum Ags (24) .
We have simulated in mice some of the factors that will have to be addressed in administering a malaria vaccine to infants in a malaria-endemic area. Priming with a DNA plasmid expressing the PyCSP in the neonatal period (7 days of age), and boosting with a recombinant vaccine virus expressing the PyCSP 3 wk later elicited excellent protective immunity, regardless of whether the newborn had passively acquired immunity from the mother. These findings are encouraging and support the execution of similar studies in human infants.
